How FDD scope shifts when a fund buys a minority stake instead of control - less leverage, less financial engineering, far more scrutiny on growth sustainability and burn.
Almost everything a junior learns about private equity clients quietly assumes a control buyout - a fund acquiring 100%, or a clear majority, of a business, usually with a stack of debt bolted on. So when your first growth-equity engagement lands and the partner tells you to worry less about the exact net debt figure and far more about whether next year's revenue plan is real, it can feel like the rules have been rewritten. They have. Minority and growth-equity investing is a genuinely different animal, and the FDD emphasis shifts to match. Recognising which kind of deal you are on, early, and reflexing your scope accordingly, is one of the clearest marks of a mature analyst rather than a merely competent one.
A growth-equity investor typically takes a minority stake - often somewhere in the 10–40% range - in a business that is already growing, providing capital to fund expansion rather than acquiring control. Contrast that with a traditional leveraged buyout, where the sponsor takes control and layers on debt. Here there is usually little or no leverage at the deal level: the investment is largely, sometimes entirely, equity-funded. That single structural fact ripples through everything the investor needs from diligence.
Because there is no debt paydown and no financial engineering doing the heavy lifting, the sponsor's return depends almost entirely on the business genuinely growing in value. In a control LBO, a chunk of the return can come from deleveraging and multiple arbitrage even if growth is only modest. Strip the leverage out and there is nowhere to hide: if the growth thesis is wrong, the return simply is not there. That is why the diligence lens swings so hard toward the durability of growth.
There is a second consequence that is easy to miss. Because the investor is taking a minority position, it typically cannot force an exit on its own timetable - it relies on the founder and majority holders to eventually run a sale or IPO. That makes the quality of the ride matter as much as the entry price. A control buyer who overpays can still fix the business and engineer a return; a minority growth investor who backs the wrong trajectory is largely along for whatever ride the founders deliver. Diligence therefore leans into questions a control deal can afford to treat more lightly: is the growth real, is the team capable of executing the plan, and are the investor's interests contractually aligned with the people actually steering the business.
| Dimension | Control buyout (LBO) | Growth / minority |
|---|---|---|
| Stake acquired | 100% or clear majority | Typically 10–40% |
| Leverage at deal level | High (often 4–6x EBITDA) | Little to none |
| Return driver | Growth + deleveraging + multiple | Growth in value, almost entirely |
| Governance concern | Full control assumed | Information rights, protections, founder alignment |
| FDD centre of gravity | Historical EBITDA precision, net debt | Growth quality, unit economics, burn and runway |
Three areas get materially more airtime on a growth deal than they would on a standard buyout.
Just as important is knowing where to ease off, because misallocating scarce diligence hours on a growth deal is its own failure.
The skill is not doing less diligence on a growth deal - it's redeploying the same hours from net-debt precision toward growth durability. Same budget, different centre of gravity.
On a growth deal the management growth plan is not background reading - it is the primary object of diligence, because the investor is quite literally buying the plan. Your job is to pressure-test it the way you would pressure-test a set of historical accounts, and the questions are different from the ones a buyout analyst instinctively asks.
Start with the bridge from today's run-rate to the plan's exit-year target and ask what each step depends on. Is next year's revenue growth coming from customers already signed and ramping, from a pipeline the sales team has visibility on, or from a market-share assumption that requires the world to cooperate? Contracted and in-ramp revenue is worth far more than aspirational pipeline, and the gap between the two is often where the real risk sits. Then look at whether the cost base is assumed to grow sub-linearly with revenue - genuine operating leverage - or whether headcount and infrastructure scale one-for-one with the top line, in which case the "growth" never actually reaches the bottom line.
The other discipline is to separate the durable engine from the flattering one-offs. A plan that leans on a single large customer, a one-time price increase, or a related-party arrangement to hit its numbers is far more fragile than one carried by broad-based customer expansion. This is exactly where growth diligence and classic earnings-quality work meet: you are still stripping out what is not repeatable, but you are doing it to a forecast, not just to history. An analyst who can articulate which parts of the plan are load-bearing and which are decoration is doing the job the growth investor is actually paying for.
Numbers make the shift concrete. Take a software business raising a £20m minority growth round. It is growing fast but still loss-making, and the whole investment case rests on the growth being real and the runway being long enough to reach profitability.
| Metric | Figure | What it tells the investor |
|---|---|---|
| Current ARR | £12.0m | Scale of the recurring base |
| ARR growth (YoY) | 45% | Headline trajectory - but is it durable? |
| Gross revenue retention | 88% | 12% is churning before any upsell |
| Net revenue retention | 112% | Existing customers expand - a genuine positive signal |
| Monthly cash burn | £0.9m | Consumption rate against the raise |
| New investment | £20.0m | - |
| Implied runway | ~22 months | £20m ÷ £0.9m - enough to reach the next milestone? |
The story here is not the flattering 45% ARR growth headline. It is the interplay: net revenue retention of 112% means the existing base is genuinely expanding, which is exactly the quality signal a growth investor pays for - but gross retention of 88% means 12% is leaking out of the bottom and the growth is being carried by upsell to survivors. And the runway is the constraint that frames everything: £20m against £0.9m of monthly burn buys roughly 22 months. If the plan needs 30 months to reach cash breakeven, the business will be back for more money - likely at a worse time and on worse terms. On a control LBO you might barely compute these metrics; on a growth deal they are the diligence.
Growth equity and minority investing is a large and expanding segment of the market, especially across technology and consumer sectors. Firms increasingly want analysts who can flex between control-deal and minority-deal thinking rather than defaulting to the LBO playbook on every engagement. The analyst who, on day one of a new deal, quietly clocks "this is a minority growth investment, so the real risk sits in growth durability and runway, not net-debt precision" - and adjusts their instincts before the partner has to spell it out - is demonstrating genuine sector maturity, not just technical competence. It is also a differentiator worth foregrounding on your CV and in interviews: the ability to name why the scope differs, not merely that it does.
This is a favourite differentiator question precisely because it catches candidates who have only ever pattern-matched to the buyout template. Expect: "How would your due diligence differ on a minority growth investment versus a control buyout?"
A strong answer sounds like this:
"The biggest structural difference is leverage - a growth deal is usually largely equity-funded with little or no debt, so the return depends almost entirely on the business genuinely growing in value, rather than on deleveraging or financial engineering. That reshapes where I'd focus. On a control buyout I'd pour effort into normalising historical EBITDA precisely and pinning down net debt, because a lender's leverage capacity rides on those exact figures. On a growth deal I'd still do that work, but I'd shift real weight onto whether the growth is durable - I'd interrogate net and gross revenue retention, unit economics, and whether the cost base scales sub-linearly with revenue. I'd also model cash burn and runway carefully: how much the business consumes monthly and whether the raise gets it to the next milestone, because a business that runs out of money early has to raise again at a weak moment. Net-debt precision and change-of-control mechanics matter less, because there's no leverage riding on the figure and control isn't changing hands. The flip side is governance - with only a minority stake the investor needs information rights and protections instead of control, so diligence extends further into structure. The skill is redeploying the same hours, not doing less work."
That answer lands because it explains the why - the absence of leverage - and then follows the consequence through into concrete, redeployed scope on both sides.
Control deals and growth deals reward two different instincts. On a buyout you chase precision - the last pound of normalised EBITDA, the exact net-debt figure - because leverage magnifies every error. On a growth deal you chase durability - is the growth real, is the runway long enough, will the model scale - because equity is carrying the whole return with no debt to hide behind. The analyst who can hold both instincts, and switch between them on the first day of a new engagement without being told, is the one firms increasingly fight to keep. Read the deal before you read the numbers; the numbers only mean what the structure lets them mean.
The Transaction Services Interview Programme (€119.99, one-time) includes a dedicated growth-and-minority-deal module - retention metrics, burn-and-runway analysis, and how to explain why minority diligence differs from a control buyout. Enrol today.
Hundreds of candidates prepared their interviews with this programme. Those who landed the role have one thing in common: they worked the cases before walking into the room.
